These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32194011)

  • 1. The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk.
    Kohler JC; Dimancesco D
    Glob Health Action; 2020; 13(sup1):1694745. PubMed ID: 32194011
    [No Abstract]   [Full Text] [Related]  

  • 2. An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency and accountability in medicines procurement.
    Mackey TK; Cuomo RE
    Glob Health Action; 2020; 13(sup1):1695241. PubMed ID: 32194014
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches.
    Vian T
    Glob Health Action; 2020; 13(sup1):1694744. PubMed ID: 32194010
    [No Abstract]   [Full Text] [Related]  

  • 4. Recalibrating the anti-corruption, transparency, and accountability formula to advance public health.
    Wierzynska A; Steingrüber S; Oroxom R; Bauhoff S
    Glob Health Action; 2020; 13(sup1):1701327. PubMed ID: 32194013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain.
    Saeed G; Kohler JC; Cuomo RE; Mackey TK
    Expert Opin Drug Saf; 2022 Aug; 21(8):1061-1088. PubMed ID: 35714366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
    Kohler JC; Bowra A
    Global Health; 2020 Oct; 16(1):101. PubMed ID: 33081805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review.
    Griffore KA; Bowra A; Guilcher SJT; Kohler J
    Global Health; 2023 Nov; 19(1):91. PubMed ID: 38001483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (UNCAC) Compliance.
    Wong A; Perehudoff K; Kohler JC
    Glob Public Health; 2024 Jan; 19(1):2350649. PubMed ID: 38752422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting anti-corruption, transparency and accountability in the recruitment and promotion of health workers to safeguard health outcomes.
    Kirya MT
    Glob Health Action; 2020; 13(sup1):1701326. PubMed ID: 32194012
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-corruption, Transparency and Accountability: Case Study of Healthcare in the Arab Countries.
    Hunter M; Uwaydah Mardini R; El-Seblani A; Elsayed S
    Glob Health Action; 2020; 13(sup1):1704529. PubMed ID: 32194015
    [No Abstract]   [Full Text] [Related]  

  • 11. Human rights mechanisms for anti-corruption, transparency and accountability: enabling the right to health.
    Sekalala S; Masud H; Bosco RT
    Glob Health Action; 2020; 13(sup1):1699343. PubMed ID: 32194016
    [No Abstract]   [Full Text] [Related]  

  • 12. The Global Fund: why anti-corruption, transparency and accountability matter.
    Chang Z; Rusu V; Kohler JC
    Global Health; 2021 Sep; 17(1):108. PubMed ID: 34537059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploration of anti-corruption and health in international organizations.
    Bowra A; Saeed G; Gorodensky A; Kohler JC
    PLoS One; 2022; 17(8):e0269203. PubMed ID: 35917329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing transparency and accountability in national pharmaceutical systems.
    Paschke A; Dimancesco D; Vian T; Kohler JC; Forte G
    Bull World Health Organ; 2018 Nov; 96(11):782-791. PubMed ID: 30455533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I Know It When I See It: The Challenges of Addressing Corruption in Health Systems Comment on "We Need to Talk About Corruption in Health Systems".
    Kohler JC
    Int J Health Policy Manag; 2019 Sep; 8(9):563-566. PubMed ID: 31657180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital technology for health sector governance in low and middle income countries: a scoping review.
    Holeman I; Cookson TP; Pagliari C
    J Glob Health; 2016 Dec; 6(2):020408. PubMed ID: 27648255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Core Roles of Transparency and Accountability in the Governance of Global Health Public-Private Partnerships.
    Reich MR
    Health Syst Reform; 2018; 4(3):239-248. PubMed ID: 30207904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-corruption in global health systems: using key informant interviews to explore anti-corruption, accountability and transparency in international health organisations.
    Gorodensky A; Bowra A; Saeed G; Kohler J
    BMJ Open; 2022 Dec; 12(12):e064137. PubMed ID: 36549737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corruption and strengthening anti-corruption efforts in healthcare during the pandemic of Covid-19.
    Teremetskyi V; Duliba Y; Kroitor V; Korchak N; Makarenko O
    Med Leg J; 2021 Mar; 89(1):25-28. PubMed ID: 33331228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Do Nigerian Newspapers Report Corruption in the Health System?
    Abba-Aji M; Balabanova D; Hutchinson E; McKee M
    Int J Health Policy Manag; 2021 Feb; 10(2):77-85. PubMed ID: 32610718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.